Role of multimodality treatment for lung cancer

Seminars in Surgical Oncology

Volumn 18, Issue 2, 2000, Pages 143-151

  Rosell, Rafael ^a   Felip, Enriqueta ^b  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Adjuvant chemotherapy; Adjuvant radiotherapy; Clinical trials; Combined antineoplastic agents; Combined modality therapy; Dose fractionation; Drug administration schedule; Lung neoplasms; Neoadjuvant therapy; Neoplasm DNA; Neoplasm staging; Non small cell lung carcinoma; p53 gene; Prognosis; Radiation dosage; Radiation dose response relationship; Survival rate

Indexed keywords

CARBOPLATIN; CISPLATIN; GEMCITABINE; NAVELBINE; PACLITAXEL; PLATINUM;

ADVANCED CANCER; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; LUNG CANCER; LUNG NON SMALL CELL CANCER; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; REVIEW;

CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; SURVIVAL RATE;

EID: 0033964583     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2388(200003)18:2<143::AID-SSU8>3.0.CO;2-I     Document Type: Review

References (67)

1. Bains MS: Surgical treatment of lung cancer [Review]. Chest 1991;100:826-837.
2. Pearson FG, DeLarue NC, Ilves R, et al: Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung. J Thorac Cardiovasc Surg 1982;83:1-11.
3. Martini N, Flehinger BJ: The role of surgery in N2 lung cancer. Surg Clin North Am 1987;67:1037-1049.
4. Perez CA, Bauer M, Edelstein S, et al: Impact of tumor control on survival in carcinoma of the lung treated with irradiation [published erratum appears in Int J Radiat Oncol Biol Phys 1986;12:2057]. Int J Radiat Oncol Biol Phys 1986;12:539-547.
5. Rosell R, Font A, Pifarré A. et al: The role of induction (neoadjuvant) chemotherapy in stage IIIA NSCLC. Chest 1996;109 (5 Suppl 5):102s-106s.
6. Martini N, Kris MG, Flehinger BJ, et al: Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorac Surg 1993;55:1365-1374.
7. Burkes RL, Ginsberg RJ, Shepherd FA. et al: Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small cell lung cancer: results of the Toronto Phase II trial. J Clin Oncol 1992;10:580-586.
8. Sugarbaker DJ, Herndon J, Kohman LJ, et al: Results of Cancer and Leukemia Group B Protocol 8935. A multi-institutional phase II trimodality trial for stage IIIA(N2) non-small cell lung cancer. J Thorac Cardiovasc Surg 1995;109:473-485.
9. Pass HI, Pogrebniak HW, Steinberg SM, et al: Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. Ann Thorac Surg 1992;53:992-998.
10. Roth JA, Fossella F, Komaki R, et al: A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer. J Natl Cancer Inst 1994;86:673-680.
11. Rosell R, Gómez-Codina J, Camps C, et al: A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer. N Engl J Med 1994; 330:153-158.
12. Roth JA, Atkinson EN, Fossella F, et al: Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer. Lung Cancer 1998;21:1-6.
13. Rosell R, Gómez-Codina J, Camps C, et al: Preresectional chemotherapy in stage IIIA non-small cell lung cancer: definitive analysis of a randomized controlled trial. Lung Cancer 1999;47:7-14.
14. Rosell R, López-Cabrerizo MP, Astudillo J: Preoperative chemotherapy for stage IIIA non-small cell lung cancer [Review]. Curr Opin Oncol 1997;9:149-155.
15. Albain KS, Rusch VW, Crowley JJ, et al: Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA(N2) and IIIB non-small cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 1995;13:1880-1892.
16. Albain K, Rush V, Crowley J, et al: Long-term survival after concurrent cisplatin/etoposide (PE) plus chest radiotherapy (RT) followed by surgery in bulky, stages IIIA(N2) and IIIB non-small cell lung cancer (NSCLC): 6-year outcomes from Southwest Oncology Group Study 8805 [Abstract]. Proc Am Soc Clin Oncol 1999;18: 467a, #1801.
17. Choi NC, Carey RW, Daly W, et al: Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small cell lung cancer. J Clin Oncol 1997;15:712-722.
18. Eberhardt W, Wilke H, Stamatis G, et al: Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small cell lung cancer: mature results of a phase II trial. J Clin Oncol 1998;16:622-634.
19. Thomas M, Rube C, Semik M, et al: Impact of preoperative bimodality induction including twice-daily radiation on tumor regression and survival in stage III non-small cell lung cancer. J Clin Oncol 1999;17:1185-1193.
20. Splinter TA, Kirkpatrick A, van Meerbeeck J, et al: Randomized trial of surgery vs. radiotherapy in patients with stage IIIA non-small cell lung cancer after response to induction chemotherapy. Intergroup study 08941 [Abstract]. Proc Am Soc Clin Oncol 1998;17:453a, #1742.
21. Fleck J, Camargo J, Godoy D, et al: Chemoradiation therapy alone vs. chemotherapy alone as a neoadjuvant treatment for stage III non-small cell lung cancer. Preliminary report of a phase III, randomized trial [Abstract]. Proc Am Soc Clin Oncol 1993;12:333a, #1108.
22. Thomas M, Rübe C, Semik M, et al: Randomized trial of chemotherapy (CT) and twice-daily chemoradiation (hfRT/CT) vs. chemotherapy (CT) alone before surgery in stage III non-small cell lung cancer (NSCLC): Interim analysis of toxicity [Abstract]. Proc Am Soc Clin Oncol 1999;18:458a, #1769.
23. Rosell R: The integration of newer agents into neoadjuvant therapy [Review]. Semin Oncol 1998;25(3 Suppl 8):24-27.
24. Bonomi P, Kim K, Kusler J, Johnson D: Cisplatin/etoposide vs paclitaxel/cisplatin/G-CSF vs paclitaxel/cisplatin in non-small cell lung cancer. Oncology 1997;11(4 Suppl 3):9-10.
25. Cardenal F, Lopez-Cabrerizo MP, Antón A, et al: Randomized phase III study of gemcitabine-cisplatin vs. etoposide-cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 1999;17:12-18.
26. Van Zandwijk N, Crino L, Kramer GW et al: Phase II study of gemcitabine plus cisplatin as induction regimen for patients with stage IIIA non-small cell lung cancer by the EORTC lung cancer cooperative group (EORTC 08955) [Abstract]. Proc Am Soc Clin Oncol 1998;17:468a, #1799.
27. Betticher DC, Hsu Schmitz SF, Gauthier Y, et al: Neoadjuvant chemotherapy with docetaxel (DOC, taxotere) and cisplatin (cis) in patients (pts) with non-small cell lung cancer (NSCLC), stage IIIA,N2 is highly active with few toxicities [Abstract]. Proc Am Soc Clin Oncol 1999;18:473a, #1824.
28. Sánchez-Céspedes M, Monzó M, Rosell R, et al: Detection of chromosome 3p alterations in serum DNA of non-small cell lung cancer patients. Ann Oncol 1998;9:113-116.
29. Esteller M, Sánchez-Cespedes M, Rosell R, et al: Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients [published erratum appears in Cancer Res 1999;59:3853]. Cancer Res 1999;59:67-70.
30. Monzó M, Rosell R, Sanchez JJ, et al: Paclitaxel resistance in non-small cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol 1999;17:1786-1793.
31. Pisters KM, Ginsberg RJ, Putnam JB, et al: Induction paclitaxel and carboplatin (PC) in early stage non-small cell lung cancer (NSCLC): early results of a completed phase II trial [Abstract]. Proc Am Soc Clin Oncol 1999;18:467a, #1800.
32. Depierre A, Milleron B, Moro D, et al: Phase III trial of neo-adjuvant chemotherapy (NCT) in resectable stage I (except T1NO), II, IIIa non-small cell lung cancer: the French experience [Abstract]. Proc Am Soc Clin Oncol 1999;18:465a, #1792.
33. Dillman RO, Seagren SL, Propert KJ, et al: A randomized trial of induction chemotherapy plus high-dose radiation vs. radiation alone in stage III non-small cell lung cancer. N Engl J Med 1990; 323:940-945.
34. Dillman RO, Herndon J, Seagren SL, et al: Improved survival in stage III non-small cell lung cancer: seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst 1996;88:1210-1215.
35. Le Chevalier T, Arriagada R, Quoix E, et al: Radiotherapy alone vs. combined chemotherapy and radiotherapy in non-resectable non-small cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991;83:417-423.
36. Sause WT, Scott C, Taylor S, et al: Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small cell lung cancer. J Natl Cancer Inst 1995;87:198-205.
37. Sause WT, Scott C, Taylor S, et al: RTOG 8808 ECOG 4588, Preliminary analysis of a phase III trial in regionally advanced unresectable non-small cell lung cancer with minimum three year follow-up [Abstract]. Int J Radiat Oncol Biol Phys 1995;32:195.
38. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Non-small Cell Lung Cancer Collaborative group. BMJ 1995;311(7010):899-909.
39. Pritchard RS, Anthony SP: Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable non-small cell lung cancer. A meta-analysis [published erratum appears in Ann Intern Med 1997;126:670]. Ann Intern Med 1996;125:723-729.
40. Soresi E, Clerici M, Grilli R, et al: A randomized clinical trial comparing radiation therapy v radiation therapy plus cis-dichlorodiammine platinum (II) in the treatment of locally advanced non-small cell lung cancer. Semin Oncol 1988;15(6 Suppl 7):20-25.
41. Trovo MG, Minatel E, Franchin G, et al: Radiotherapy vs. radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1992;24:11-15.
42. Schaake-Koning C, van den Bogaert W, Dalesio O, et al: Effect of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med 1992;326:524-530.
43. Lee JS, Scott C, Komaki R, et al: Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell lung cancer: Radiation Therapy Oncology Group protocol 91-06. J Clin Oncol 1996;14:1055-1064.
44. Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S: Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small cell lung cancer: a randomized study. J Clin Oncol 1996;14:1065-1070.
45. Furuse K, Fukuoka M, Takada Y, et al: A randomized phase II study of concurrent vs. sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer: preliminary analysis [Abstract]. Proc Am Soc Clin Oncol 1997;16:459a, #1649.
46. Furuse K, Fukuoka M, Takada Y, et al: Phase III study of concurrent vs sequential thoracic radiotherapy (TRT) in combination with mitomycin (M), vindesine (V) and cisplatin (P) in unresectable stage non-small cell lung cancer (NSCLC): Five-year median follow-up results [Abstract]. Proc Am Soc Clin Oncol 1999;18:458a, #1770.
47. Clamon G, Herndon J, Cooper R, et al: Radiosensitization with carboplatin for patients with unresectable stage III non-small cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol 1999;17:4-11.
48. Cox JD, Azarnia N, Byhardt RW, et al: A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11. J Clin Oncol 1990;8: 1543-1555.
49. Saunders M, Dische S, Barrett A, et al: Continuous hyperfractionated accelerated radiotherapy (CHART) vs. conventional radiotherapy in non-small cell lung cancer: a randomised multicentre trial. CHART Steering Committee. Lancet 1997;350(9072):161-165.
50. Armstrong JG: Target volume definition for three-dimensional conformal radiation therapy of lung cancer [Review]. Br J Radiol 1998;71:587-594.
51. Hayman JA, Martel MK, Ten Haken RK, et al: Dose escalation in non-small cell lung cancer (NSCLC) using conformal 3-dimensional radiation therapy (C3DRT): update of a phase I trial [Abstract]. Proc Am Soc Clin Oncol 1999;18:459a, #1772.
52. Chen LM, Ignacio L, Jacobs R, et al: Results of a phase II concurrent chemoradiotherapy study using three-dimensional conformal radiotherapy with cisplatin and oral etoposide in stage III non-small cell lung cancer. Radiat Oncol Invest 1999;7:49-53.
53. Belani CP: Incorporation of paclitaxel and carboplatin in combined-modality therapy for locally advanced non-small cell lung cancer [Review]. Semin Oncol 1999;26(1 Suppl 2):44-54.
54. rd: Concurrent paclitaxel, carboplatin, and radiation therapy for locally advanced non-small cell lung cancer [Review]. Semin Oncol 1999;26(1 Suppl 2):36-43.
55. Vokes EE, Leopold KA, Herndon JE, et al: A randomized phase II study of gemcitabine or paclitaxel or vinorelbine with cisplatin as induction chemotherapy (Ind CT) and concomitant chemoradiotherapy (XRT) for unresectable stage III non-small cell lung cancer (NSCLC) (CALGB Study 9431) [Abstract]. Proc Am Soc Clin Oncol 1999;18:459a, #1771.
56. Boral AL, Skarin AT, Lynch CM, et al: A phase I study of carboplatin (car) and docetaxel (doc) followed by weekly car/doc with concurrent radiotherapy in patients with stage III NSCLC [Abstract]. Proc Am Soc Clin Oncol 1999;18:483a, #1864.
57. Kandioler-Eckersberger D, Kappel S, Mittlböck M, et al: The TP53 genotype but not immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III non-small cell lung cancer. J Thorac Cardiovasc Surg 1999;117:744-750.
58. Mitsudomi T: Targeting p53 for diagnosis and therapy in lung cancer. Rev Oncol 1999;1(Suppl 2):2-8.
59. Garrido MP, Moyano A, Lago J, et al: Multidisciplinary approach including surgery in stage IIIB non small cell lung cancer patients. Rev Oncol 1999;1(Suppl 2):61-69.
60. Rendina EA, Venuta F, De Giacomo T, et al: Induction chemotherapy for T4 centrally located non-small cell lung cancer. J Thorac Cardiovasc Surg 1999;117:225-233.
61. Grunenwald D, Le Chevalier T: Stage IIIA category of non-small cell lung cancer: a new proposal [letter: comment] [published erratum appears in J Natl Cancer Inst 1997;89:328] J Natl Cancer Inst 1997;89:88-89.
62. Ruckdeschel JC: Combined modality therapy of non-small cell lung cancer [Review]. Semin Oncol 1997;24:429-439.
63. Kubota K: Chemoradiotherapy in stage III non-small cell lung cancer: is surgery still necessary? Rev Oncol 1999;1(Suppl 2):58-60.
64. Sorensen JB: Neoadjuvant chemotherapy for locally advanced non-small cell lung cancer. Rev Oncol 1999;1(Suppl 2):26-30.
65. Wang J, Olak J, Ferguson MK: Diffusing capacity predicts operative mortality but not long-term survival after resection for lung cancer. J Thorac Cardiovasc Surg 1999;117:581-587.
66. Smetana GW: Preoperative pulmonary evaluation [Review]. N Engl J Med 1999;340:937-944.
67. Torres García AJ, Hernando Trancho F, Gómez Martínez A, et al: Postoperative care after neoadjuvant chemotherapy in stage IIIA non-small cell lung carcinoma (NSCLC). Rev Oncol 1999;1(Suppl 2): 55-57.